Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Beigene Ltd ADR (BGNE)

Beigene Ltd ADR (BGNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,174,338
  • Shares Outstanding, K 97,343
  • Annual Sales, $ 2,459 M
  • Annual Income, $ -881,710 K
  • EBIT $ -883 M
  • EBITDA $ -795 M
  • 60-Month Beta 0.63
  • Price/Sales 8.08
  • Price/Cash Flow N/A
  • Price/Book 5.88

Options Overview Details

View History
  • Implied Volatility 52.23% ( -0.90%)
  • Historical Volatility 38.08%
  • IV Percentile 82%
  • IV Rank 70.94%
  • IV High 61.61% on 08/05/24
  • IV Low 29.34% on 08/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 127
  • Put/Call OI Ratio 1.06
  • Today's Open Interest 4,392
  • Open Int (30-Day) 4,601

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.88
  • Number of Estimates 5
  • High Estimate -0.18
  • Low Estimate -1.62
  • Prior Year 2.01
  • Growth Rate Est. (year over year) -143.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
202.19 +2.84%
on 10/31/24
247.50 -15.99%
on 10/07/24
-38.11 (-15.49%)
since 10/04/24
3-Month
166.55 +24.85%
on 08/06/24
248.16 -16.21%
on 10/04/24
+42.27 (+25.52%)
since 08/05/24
52-Week
126.97 +63.77%
on 04/19/24
248.16 -16.21%
on 10/04/24
+24.15 (+13.14%)
since 11/03/23

Most Recent Stories

More News
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

ONCY : 1.1800 (+3.51%)
BGNE : 208.03 (+0.38%)
HCM : 18.62 (+1.31%)
ABBV : 201.68 (+0.60%)
ONC.TO : 1.63 (+1.87%)
ELVN : 28.01 (+1.30%)
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

/CNW/ -- USA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers among...

ONCY : 1.1800 (+3.51%)
BGNE : 208.03 (+0.38%)
HCM : 18.62 (+1.31%)
ABBV : 201.68 (+0.60%)
ONC.TO : 1.63 (+1.87%)
ELVN : 28.01 (+1.30%)
Investors Watch Key Players in Oncology as Cancer Cases Set to Skyrocket

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – The surge in...

ONCY : 1.1800 (+3.51%)
BGNE : 208.03 (+0.38%)
EXEL : 34.77 (+1.40%)
ABBV : 201.68 (+0.60%)
ONC.TO : 1.63 (+1.87%)
AMGN : 319.29 (+0.75%)
Is Regeneron Pharmaceuticals Stock Outperforming the S&P 500?

Regeneron Pharmaceuticals has outperformed the broader S&P 500 Index over the past year, and Wall Street analysts remain bullish on the stock’s prospects.

REGN : 829.43 (+0.07%)
$SPX : 5,782.76 (+1.23%)
$SPX : 5,782.76 (+1.23%)
BGNE : 208.03 (+0.38%)
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?

The big pharma company's top drug is losing ground, but its dividend keeps rising.

CVS : 55.34 (+1.26%)
UNH : 567.03 (+1.66%)
ABT : 117.73 (+0.07%)
CI : 318.39 (+1.94%)
AZN : 66.27 (-7.22%)
BGNE : 208.03 (+0.38%)
RVNC : 5.84 (+0.52%)
ABBV : 201.68 (+0.60%)
Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

/CNW/ - BeiGene, Ltd. (Nasdaq: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, today announced it received Health Canada authorization for...

BGNE : 208.03 (+0.38%)
Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access, through public reimbursement, to BRUKINSA® (zanubrutinib)

/CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company is pleased to announce that the Governments of Ontario and...

BGNE : 208.03 (+0.38%)
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond

These five biotech companies could have a lot of room to run.

AMGN : 319.29 (+0.75%)
ARGX : 602.47 (+2.34%)
BGNE : 208.03 (+0.38%)
CRSP : 50.36 (-0.45%)
IMVT : 30.32 (+3.06%)
7 Best Cancer Stocks to Invest in Now

The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.

EXEL : 34.77 (+1.40%)
GILD : 90.22 (+0.42%)
NVS : 109.38 (-1.03%)
ON : 70.20 (+1.01%)
PFE : 27.99 (+0.83%)
MDCO : 84.90 (-0.07%)
MRK : 101.65 (-0.22%)
KURA : 17.52 (-1.63%)
AZN.LN : 10,114.000 (-8.40%)
BGNE : 208.03 (+0.38%)
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

GILD : 90.22 (+0.42%)
AMGN : 319.29 (+0.75%)
BMY : 55.95 (+0.90%)
NVS : 109.38 (-1.03%)
BGNE : 208.03 (+0.38%)
JSPR : 22.40 (+1.68%)
VIGL : 3.86 (-0.26%)
ALVR : 0.9899 (+11.60%)
RCUS : 15.29 (-1.74%)
FLACU : 9.50 (+2.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.

See More

Key Turning Points

3rd Resistance Point 215.89
2nd Resistance Point 213.21
1st Resistance Point 210.23
Last Price 208.03
1st Support Level 204.57
2nd Support Level 201.88
3rd Support Level 198.90

See More

52-Week High 248.16
Last Price 208.03
Fibonacci 61.8% 201.86
Fibonacci 50% 187.56
Fibonacci 38.2% 173.26
52-Week Low 126.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar